Join the Bladder Cancer group to help and get support from people like you.
Bladder Cancer News
Related terms: Cancer, Bladder
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant...
Multiparametric MRI Expedites Treatment in Muscle-Invasive Bladder Cancer
FRIDAY, Jan. 24, 2025 – Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder...
New Therapy Helps Patients With Tough-to-Treat Bladder Cancers
FRIDAY, Dec. 6, 2024 – There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report. An experimental new drug with the unwieldy name of...
MS Might Raise a Person's Odds for Cancer
THURSDAY, Oct. 10, 2024b – There's a small but significant increased of certain cancers in people battling multiple sclerosis (MS), new research shows. Those malignancies include cancers of the...
Extended Lymphadenectomy Fails to Improve Survival in Bladder Cancer
THURSDAY, Oct. 3, 2024 – For patients with muscle-invasive bladder cancer, extended lymphadenectomy does not improve disease-free or overall survival compared with standard lymphadenectomy,...
Post-Op Keytruda Boosts Bladder Cancer Outcomes
WEDNESDAY, Sept. 18, 2024 – When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds. Folks with "high-risk"...
Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers
FRIDAY, Sept. 6, 2024 – Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and...
Ruling Out Other Conditions Needed With Suspected Interstitial Cystitis
WEDNESDAY, Sept. 4, 2024 – Efforts to rule out bladder tumors and tuberculosis are still essential in the follow-up of patients with suspected interstitial cystitis (IC), according to a study...
Pesticides Can Equal Smoking in Hiking Risks for Cancer
THURSDAY, July 25, 2024 – Farmers and folks living in agricultural areas may be exposed to levels of pesticides that confer cancer risks that are higher than if they smoked, new research shows....
FDA Approves Anktiva (nogapendekin alfa inbakicept-pmln) Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif., April 22, 2024 -- ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved Anktiva (N-803, or ...
Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
Padcev plus pembrolizumab approved based on groundbreaking EV-302 trial Confirmatory trial found Padcev plus pembrolizumab nearly doubled median overall survival compared to standard of care...
FDA Approves Adstiladrin (nadofaragene firadenovec-vncg) for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Ferring’s novel adenovirus vector-based gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) is the first gene therapy approved for bladder cancer Efficacy and safety of Adstiladrin supported by...
Genentech Provides Update on Tecentriq U.S. Indication for Previously Untreated Metastatic Bladder Cancer
South San Francisco, CA – November 28th, 2022 -- Genentech, a member of the Roche Group, today announced that the company is voluntarily withdrawing the U.S. indication of Tecentriq® (atezolizumab) f...
FDA Approves Keytruda (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) January 8, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Padcev (enfortumab vedotin-ejfv) for Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder Cancer
TOKYO and BOTHELL, Wash., Dec. 18, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced ...